ATS 2023 Respiratory Innovation Summit
During the ATS 2023 Respiratory Innovation Summit, APIE Therapeutics presented a poster demonstrating preclinical efficacy of APT101 in a lung fibrosis model
APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood, former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors. “Jim is known in the industry for his long tenure as president and CEO […]
IPF Summit 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist (APT101) and its effects in models of acute and chronic lung injury
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
